Showing posts with label IBC. Show all posts
Showing posts with label IBC. Show all posts

Wednesday, April 13, 2016

Peptides for CNS and Alzheimer's Disease Therapy

Exclusive TIDES 2016 interview with Dieter Willbold, Ph.D., Director, ICS-6 Structural Biochemistry, Forschungszentrum Jülich, Germany. Dr. Willbold gives us some exclusive insights into the topics he will be addressing onstage at the 18th annual TIDES in just 4 weeks time. Don't miss out on this record setting meeting; join over 800 global attendees over 4 days full of insights and learnings. Register for TIDES by Friday, 4/15 and save $300 - Use the code B16180BLOG.


Dr. Willbold Interview: 

What current challenges are you facing for advancing your promising peptide for Alzheimer's disease through clinical trials?

Our main focus at the moment is to finish all the necessary preclinical tox and safety tests in order to soon get permission for a clinical phase I study with our drug candidate.

One challenge for developing therapeutics like ours that target specific aggregate species, lies in the lack of suitable analytics to measure target engagement, because most methods don't differentiate between different aggregate sizes. In addition to cognitive behavioral tests, we ourselves have therefore developed novel methods to measure efficacy and target engagement .e.g. QIAD (short for quantitative determination of interference with aggregate size distribution; Brener et al., Scientific Reports 2015), which measures Abeta oligomer elimination efficiency.


What are the advantages of peptide therapeutics over small molecules, antibodies and other protein therapeutics?

Small molecules often lack specificity, and this can lead to serious side effects and autoimmune responses. On the other hand protein-based therapeutics like antibodies possess high target selectivity and are made of natural components, but they are very big and expensive molecules. They often suffer from low oral bioavailability.

Small peptides can offer the best of both worlds in some respects: They are more target specific than small molecules but easier to produce than protein based drugs. Our drug candidate is made solely from D-enantiomeric amino acid residues and has surprisingly good oral bioavailability.


Where do you see innovation happening in the peptide field over the next 5 years?

Innovation will certainly happen in the production of peptides (cost reduction) and in the formulation of peptides (increase oral bioavailability).


______________________________________________________



Reserve your seat today to attend TIDES 2016 in Long Beach, CA and hear Dr. Willbold deliver a live presentation "Efficiency and Oral Bioavailability of Abeta Oligomer Directed D-Enantiomeric Peptides Developed for Therapy of Alzheimer's Disease", where he will delve into small soluble Abeta oligomers are suspected to be the major toxic species responsible for development and progression of Alzheimer's disease (AD). We developed highly potent D-enantiomeric peptide compounds that specifically eliminate Abeta oligomers and improve cognitive performance and stop or slow down neurodegeneration of AD transgenic mice. Data on stability and oral bioavailability clearly support the superiority of D-peptides over L-peptides.





Share this article with your social network, just click below to share now!


Monday, April 11, 2016

Record Attendance Expected! Don't Miss IBC's 18th Annual TIDES


Register by Friday, April 15th and save $300! To save, use the code B16180BLOG100



Experts Provide Key Success Factors for Drug Development and Manufacturing:

Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors
Richard DiMarchi, Ph.D. Standiford H. Cox Professor of Chemistry, Indiana University

Drisapersen: Case Study
Robert Baffi, Ph.D. Executive VP, Technical Operations, BioMarin Pharmaceuticals

Quark's Long History of Oligonucleotide Development
Danny Zurr, Ph.D. Chairman and CEO, Quark Pharmaceuticals Inc. 

Technologies for Targeting Molecules to Sites of Diseases
John Reed MD, Ph.D Global Head of Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.


TIDES 2016 is on pace for record attendance with 800+ global attendees expected to attend this year’s meeting, held May 9-12, 2016 in Long Beach, California – will you be there?

Register your team today and access the science, technologies and contracts you need to accelerate your oligonucleotide and peptide products through the clinic towards commercial success.

Your registration grants you access to:
  • 800+ attendees representing 25 countries help you forge new business and scientific collaborations
  • 100+ speaker presentations across 5 tracks provide a customized agenda of solutions for your company’s current challenges
  • 70+ exhibitors demonstrate the latest products and technologies to accelerate your therapeutic to market
  • 40+ poster presentations keep you abreast of cutting-edge industry and academic research

Plus, be sure to register this week to gain access to Attendee Connect powered by partneringONE, the digital networking platform that allows you to view the full attendee list, pre-schedule meetings, and send private messages to attendees before, during and after the event.



Share this article with your social network, just click below to share now!


Tuesday, March 29, 2016

The Current Value of the Global Peptide Therapeutics Market



"The number of companies specializing in the manufacture of therapeutic peptides has been shrinking over the last 15 years with fewer new companies entering the market than those leaving it."  

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA. 


In this interview, Dr. Lax discusses:
  • - The current estimated value of the global peptide therapeutics market.
  • - The key factors that contribute to the constant growth of the global peptide therapeutics market.
  • - The advantages/disadvantages to a consolidated peptide manufacturing industry.
  • - Which emerging markets are leading the forefront of peptide therapeutics research and development
  • - Opportunities that are emerging due to recent advancements in manufacturing and delivery technology

 Access the complete interview here.

PLUS! As a blog reader, you are eligible to save $300 when registering for TIDES. Use the code B16180BLOG100 to activate your savings. Click here to register.


Share this article with your social network, just click below to share now!


Tuesday, February 16, 2016

Efficient Chemoenzymatic Peptide Synthesis (CEPS) in Water


"When peptides are ligated in water, the crude reaction mixture can immediately be loaded on the preparative HPLC column to purify the product" 

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Timo Nuijens, Ph.D., Lead Scientist, EnzyPep BV, The Netherlands for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

Efficient Chemoenzymatic Peptide Synthesis (CEPS) in Water
We describe a novel, organic cosolvent-stable peptide ligase (peptiligase), which couples peptide fragments with exceptional efficiency in water. Because peptiligase does not need a particular recognition motif, this novel technology is traceless and very broadly applicable. Besides fragment condensation, the enzyme is able to efficiently catalyze head-to-tail cyclization of peptides to create macrocyclics. It has also been shown to couple peptide esters efficiently to proteins. Peptiligase could be a useful tool for the (industrial) synthesis of numerous (pharmaceutical) peptides and conjugates.

In this interview, Dr. Nuijens also discusses;
  • The importance of fragment condensation of peptides in water
  • What the future holds for the Netherlands in the global peptide drug development market
  • The factors to consider when determining the optimal synthesis strategy when screening an enzyme

Register for TIDES now and save $500 - To save, use the code B16180BLOG100


Share this article with your social network, just click below to share now!


Thursday, December 17, 2015

Announcing: TIDES 2016 Keynote Lineup | Brochure is Now Available



IBC’s 18th Annual TIDES meeting is coming to Long Beach, CA May 9-12, 2016. TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization.

RVSP by January 29th, 2016 with code B16180LINK100 and receive $600 savings off the standard rate. Secure your best rate now.

Keynote and Featured Speakers Provide Novel Strategies to Accelerate Product Approval:

  • Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors
    • • Richard DiMarchi, Ph.D. Professor of Chemistry | Indiana University
  • Drisapersen: Case Study
    • • Robert Baffi, Ph.D., Executive VP, Technical Operations | BioMarin Pharmaceutical
  • Quark's Long History of Oligonucleotide Development
    • • Danny Zurr, Ph.D., Chairman and CEO | Quark Pharmaceuticals Inc.
  • Technologies for Targeting Molecules to Sites of Disease
    • • John Reed, M.D., Ph.D. Global Head | Roche Pharma, Switzerland


TIDES by the numbers:
  • 800+ attendees representing global innovators, suppliers and thought-leaders who can expand your pipeline and grow your business
  • 100+ case studies and new data presentations providing novel strategies to accelerate your product to market
  • 70+ exhibitors showcasing new technologies to improve your process development, analytical and manufacturing/scale-up efforts


Sponsorship and Exhibition Opportunities
Showcase your expertise to 800+ global buyers by becoming an event sponsor or exhibitor at TIDES. A wide variety of options are available to meet your company's goals and budget. Contact Patrick Gallagher pgallagher@ibcusa.com for pricing and package details.





Share this article with your social network, just click below to share now!


Monday, November 30, 2015

Celebrate Cyber Monday with 25% Off IIR and IBC Pharma and Life Sciences Events

Use code CYBER25 for 25% off the current rate TODAY ONLY. For this exclusive savings use code CYBER25 to register today, November 30th for all the below IIR and IBC Life Sciences pharmaceutical and life sciences conferences:

Antibody Engineering & Therapeutics
December 7-10, 2015
San Diego Convention Center
San Diego, CA
Discount code: CYBER25
Download the brochure: http://bit.ly/1MZnpHL

RIM
Regulatory Information Management Summit
December 14-15, 2015
Ritz Cartlon
Washington DC
Discount code: CYBER25
Download the brochure: http://bit.ly/1lU3rYj

FDA/CMS Summit
December 14-15, 2015
Washington DC
Discount code: CYBER25
View the agenda: http://bit.ly/1lpMvs8

Drug Delivery Partnerships
January 20-22, 2015
PGA National Resort & Spa
Palm Beach Gardens, FL
Discount code: CYBER25
Download the brochure: http://bit.ly/1QPkxU0

Asia TIDES
February 24-26, 2016
Westin Miyako Kyoto
Kyoto, Japan
Discount code: CYBER25
Download the brochure: http://bit.ly/1lU53S2

ePharma
February 29-March 2, 2016
Sheraton Times Square
New York, NY
Discount code: CYBER25
Download the brochure: http://bit.ly/1YD9hLV

BioProcess International Conference & Exposition West
March 14-17, 2016
Oakland Marriott City Center
Oakland, CA
Discount code: CYBER25
View the preliminary agenda: http://bit.ly/1OzE7A6

TIDES
May 9-12, 2016
Long Beach Convention Center and Entertainment Center
Long Beach, CA
Discount code: CYBER25
Download the brochure: http://bit.ly/1OqjtEp

We hope to see you at our 2015-16 events!

*All registrations are subject to approval. Discounts cannot be retroactively applied*

Cheers,
The IIR and IBC Life Sciences Teams






Share this article with your social network, just click below to share now!


Wednesday, September 23, 2015

Bioprocessing Cell Therapy Products Demands Greater Automation

Cell therapy bioprocessing is undergoing significant developments at the moment. Bioprocess engineers that have developed their skills on vaccine or recombinant protein production will recognise the types of challenges experienced by those attempting to manufacture cell therapies, namely, process development, innovation, operations and process transfer, process characterization and the setting of specifications.

Finding solutions to process and technology cell therapy bottlenecks is the topic of a presentation at the Cell Therapy Bioprocessing BPI Boston, Pre-Conference Symposium from invited speaker Nick Timmins. Nick has previously co-authored a review of cell therapy bioprocessing in BioProcess International 12(3) March 2014 entitled ‘Cell Therapy Bioprocessing Technologies and Indicators of Technological Convergence’.

Increased Sensitivity to the Bioprocess Environment

In the review the authors describe how cells in cell therapy bioprocesses are “biologically dynamic” and highly sensitive to the bioprocess environment in which they are produced. This will have a direct impact on a cell therapies critical quality attributes. In contrast, industrial cell lines that are typically used to produce recombinant proteins are more stable during processing and the final protein product are less directly dependent on the culture and processing environment.

Bioprocess automation mitigates risks in patient-specific therapy production

Bioprocessing technologies used for cell therapy manufacture typically require a higher level of automation which allows for a greater level of control of the bioproduction environment which can impact product CQAs, however it also enables operators to run multiple upstream and downstream protocols simultaneously to produce, what could be, patient-specific therapies. The patient-specific nature of some cell therapies adds in an additional layer of complexity to the processing requirements, not typically found in biomanufacturing, driven by the need to prevent the mishandling or cross contamination of patient tissues. Process automation can help mitigate against some of these risks through ensuring the rigorous control and identification of biological materials as they are produced. More manual process interventions increase the opportunities for errors, contaminations and even abuse.  

The BioProcess International Conference and Exposition will be held on October 26-29, 2015 in Boston and the Cell Therapy Pre-Conference Symposium is scheduled to take place on October 26th.

Join me at #BPIconf
Contact me at nick.hutchinson@parker.com


Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Monday, September 21, 2015

Closed Systems in Biomanufacturing Offer a Variety of Benefits


I recently attended IBC’s Biopharmaceutical Development and Production week (BDP) and was pleased to find talks focused on single-use technologies, flexible facilities, closed systems and continuous processing. These subjects are sometimes referred to as “biomanufacturing of the future,” because they represent a change in paradigm from traditional biomanufacturing. While we have covered single-use and continuous bioprocessing extensively on Cell Culture Dish in the past, we have not dedicated much time covering the benefits and opportunities associated with closed systems. This blog will attempt to provide a high-level review of some of the topics associated with closed systems and will provide several outside resources for readers who want to explore the topic in more detail.

Traditional Biopharmaceutical Manufacturing

Traditional biopharmaceutical manufacturing has mainly consisted of fed-batch stainless steel bioreactor runs in a fixed facility with an open system. This paradigm, while serving the biopharmaceutical industry well for many years, has faced increasing pressure as single product 20,000L scale manufacturing has begun to lose ground to smaller volume, multi-product manufacturing. This shift has occurred for several reasons, some include:

·         Increases in productivity have reduced the need for very large scale manufacturing vessels and dedicated facilities.
·         Fewer blockbuster drugs with high volumes have reduced the need for large-scale dedicated facilities.
·         Single-use technologies have enabled the implementation of smaller, more flexible manufacturing.
·         Companies have begun to embrace the idea of more flexible, multi-product facilities that can easily be scaled up or down to meet changing product demand.

As a result of the changing landscape, the traditional biomanufacturing paradigm has been challenged by new models including flexible facilities, single-use systems and continuous processes that can create a more flexible and in many cases more cost effective process. Biomanufacturing of the future incorporates technologies like single-use and models like closed systems and continuous processing to move the industry forward.

Closed and Functionally Closed Systems

There have been several definitions of what makes a closed or functionally closed system in biomanufacturing. All the definitions are similar, but I like the definitions used in the BioPharm International article “Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances.” The article provides the following definitions:
  • Closed system: A process system with equipment designed and operated such that the product is not exposed to the room environment. Materials may be introduced to a closed system, but the addition must be done in such a way to avoid exposure of the product to the room environment (e.g., by 0.2 μm filtration).
  • Functionally closed system: A process system that may be routinely opened (e.g., to install a filter or make a connection), but is returned to a closed state through a sanitization or sterilization step prior to process use. It is the owner’s responsibility to define and validate the sanitization or sterilization process required to return an opened system to a functionally closed system
Benefits of a Closed or Functionally Closed System

Reduced Risk of Contamination
One of the biggest and most easily attained benefits of implementing a closed system, whether in research, pilot or large scale, is in reducing the risk of contamination by viruses or other adventitious agents. Open systems naturally provide more opportunities for contamination because the process is open to the room environment and handling by operators. There are also safety concerns associated with breeches of product containment. Operations like fluid transfer present a much higher risk in an open system where splashing and lost media can occur. A closed system, by design, provides physical barriers to reduce the risk of contamination and contain the product.

This is important because contamination can be extremely costly, not only in product loss, but also facility shut downs, cleaning and validation.

Reduced Process Time
The use of a closed system can reduce operating time. A closed system relies on less operator handling and fewer overall steps. Another time saving factor is that many of the closed system components are plug and play meaning that they come pre-assembled, designed for the job they are intended. This reduces the time it takes to set up and launch a manufacturing system significantly.

If single use technologies are employed as part of the closed system, then more time savings can be achieved. Over the course of several talks, the use of single use technologies were reported to save anywhere from a couple of days to a couple of weeks. These times savings were reported in areas including:
  • Reduced cleaning and validation time
  • Reduced set-up time
  • Reduced time to operate or oversee equipment
Examples of Benefits
One example where there is a benefit to time savings and risk reduction is in media preparation. To enable a closed system, instead of mixing and adding media, one might purchase a pre-filled media bag with a connector that is complimentary to a single use bioreactor. This creates a closed portion of the process and saves operator time of mixing media. This method also reduces risk of contamination because the media isn’t exposed to the room environment and there is reduced risk of spilling and loss of media. Aseptic transfer of large volumes of sterile media and solution can be a big challenge.

Another example was provided in a talk at BDP, titled “Processes of the Future: Single Use, Closed and Continuous for Faster, Cheaper and Safer Manufacturing,” given by Sébastien Ribault, Ph.D., Director Biotechnology/Life Science, Head of BioDevelpment Center, EMD Millipore. BDP. In Dr. Ribault’s facility, his team is operating a closed system in one of their manufacturing areas. The group needed to close the cell seeding process, so instead of banking cells in vials, they banked the cells in bags. They then thawed the bags in a water bath and seeded directly in the lab without laminar flow. This saved them time and they reported similar growth and viability to the process using cells banked in vials.

Adopting a Risk Based Approach to Manufacturing Classifications
One hot topic in the discussion around closed systems is the idea of adopting a risk-based approach when it comes to the manufacturing classifications required with closed systems. If a system is closed, or functionally closed, then a barrier already exists between the product and its environment. Therefore, is there really a need for these operations to be conducted in a Classified environment with extensive gowning and airlocks, or would it be more feasible to conduct these operations in a Controlled Non-Classified (CNC) space? The benefits associated with this type of change in classification would provide many manufacturing benefits.

At BDP, Kenneth Green, Ph.D., Head of Manufacturing Science and Technology, Shire, gave an excellent talk titled, “Pushing the Controlled Non-Classified (CNC) Envelope with the Application of Single-Use Systems for Bioprocessing.” In the talk, Dr. Green discussed the debate around whether a closed system or functionally closed system could be proved to regulators, with satisfaction, so that manufacturing could occur in a controlled non-classified environment.

If so, operating in a Controlled Non Classified (CNC) space would open up many more benefits including:
  • Enabling a truly flexible facility – by reducing the classified area requirements you could also reduce the amount of segregation in a facility and increase flexibility. There are many benefits associated with flexible manufacturing, including:
    • Smaller facilities with a simpler design that can be duplicated in multiple locations
    • Multiple products can be manufactured in the same facility or space
    • Less segregation
    • Equipment can be moved around on skids as needed to meet product demand in multiple production lines.
    • Personnel can also move more easily throughout the facility
  • Reduced operating costs include:
    • Energy savings by reducing the environmental monitoring needed and the air handling requirements
    • Removing or reducing gowning requirements reduce cost of both gown materials and provide time savings for the gowning/de-gowning processes.
The idea of employing a risk-based approach in classification requirements is a very interesting topic that could be a blog entirely on its own; however for the purposes of this article, I am only providing a high level overview. There are a number of excellent articles that cover this topic in more detail including:



Challenges to Implementation of a Closed System

Employee Training
While most of these systems are fairly easy to use, there are some major differences between stainless steel systems and single-use. Employees should be trained in maintaining the closed or functionally closed system, proper use of equipment to prevent breakage or tears and employees need to be comfortable using the tubing and connectors.

Breaking New Ground
Completely closed systems represent relatively new technologies. Ensuring all parts of your system are closed may require a good deal of ingenuity and determination particularly when using components from several suppliers. There may not be an off the shelf component that works for you and you may need to work with suppliers to create systems that work for your process.

One example of this ingenuity and determination appeared in Dr. Veena Warikoo’s talk at BDP. Dr. Warikoo, Director, Purification Development, Genzyme, gave a talk titled “Integrated and Fully Continuous Processing of Recombinant Therapeutic Proteins – From Cell Culture Media to Purified Drug Substance.” In the talk she described how Genzyme developed a closed, continuous model system for manufacturing both mAbs and non-mAbs. They had been using a continuous system upstream but needed to also close the downstream process. There wasn’t an off the shelf solution available at the time, so they partnered with GE Healthcare to develop a functionally closed periodic counter-current chromatography continuous process. She showed a picture of the system they used, then stated that GE Healthcare now offers an off the shelf version in their AKTA system.

Demonstrating to Regulators that Systems are Closed and Adopting Risk Based Approach in Classification for Closed Systems
In order to fully gain all of the benefits mentioned above, the industry must work with regulators to demonstrate that CNC manufacturing space is appropriate. BioPhorum Operations Group (BPOG) is currently working to help interpret regulatory guidance and quality expectations and prepare responses that incorporate a risk based approach.

Is a closed system right for your process? – How to navigate a transition
I was able to speak with Erika Hanley-Onken and John Shyu at Corning Life Sciences about their experiences helping customers’ transition to closed systems. They said that they like to conduct a walk through with customers to understand on a technical level the customer’s current system and how that system will transition into a new closed system. They also work with multiple vendors to create a system designed to meet customer needs and goals. Lastly, they train the company on using the new system and they will work with customers to help validate the new system. When asked what customers are most surprised by when deciding to transition they said “how long it takes, it can take weeks to months to develop the system and test it, but we provide a full quality package and we want to ensure that the customer can achieve full and consistent results.”

Goals
First it is important to consider what is the primary goal in moving to a closed system. Some examples below:
  • Designing a new facility and want to incorporate flexible manufacturing principals
  • Quality control concerns and are interested in reducing risk of contamination
  • Process improvements with desire to reduce production time or cost
Design and Implementation of a Closed System
In determining the design and implementation of your closed system it is critical to truly understand your existing process needs, strengths and weaknesses. These factors can be very helpful when working with a vendor or vendors to establish your system. It is also important to understand your current cost of goods and net present value analysis, particularly if cost is a driving factor for change. This will allow you to compare your current system against the proposed system once you have a scale model running.

It is imperative to find a partner that you can work well with. Several talks stressed the keys to a good partnership, and I have included some of them below:
  • It is important for companies to understand their process and share this with supply partners.
  • Choose a supplier you trust and can work with. They have to know what your concerns and goals are so they can build a system that works for you.
  • A supplier should have a quality package and service to help with validating the new system.
Supply partners can be a single vendor who will work to design a process using theirs and complimentary products. A company may also choose a supply partner that has the capability to utilize multiple product vendors to put together a system that is compatible.
This blog was first published on CellCultureDish.com




Share this article with your social network, just click below to share now!


Wednesday, September 16, 2015

Top 10 Reasons to Attend BioProcess International 2015 This Fall

BioProcess International Conference & Exposition is the largest bioprocessing event bringing you new ideas, demystifying technology, and fostering partnerships in highly engaging formats to move drug candidates closer to approval. Register today to attend this year’s meeting, held October 26-29, 2015 at the Hynes Convention Center in Boston, MA.

At the conference, formal and informal networking experiences will connect you to peers, prospects, and customers; parallel tracks give you the option to dive deep or take a big picture approach to learn about industry trends, challenges, and benchmark against the latest research developments and; big pharma and large, mid-size and emerging biotechs collaborating with solution providers will feature proven and next generation technologies – making BPI a one-of-a-kind meeting place.

Above all, here are the top 10 reasons we think BPI is the right bioprocessing event for you:

1.       More than 150+ comprehensive solution providers, next generation technologies, and start-ups – all in one place inside the exposition hall.
2.       6 tracks for one fee. Go specialized or expand your horizons across disciplines for a personalized, curated content experience.
3.       Back by Popular Demand! BPI Theater, a curated showcase of the best innovations.
4.       NEW! Town Hall Forums for highly focused industry best practice sharing.
5.       New and Improved! BPI Connect Partnering App to help jump start your next partnership or collaboration.
6.       NEW! Exposition Hall Tour for focused exhibit viewing led by an industry insider.
7.       NEW! Ask the Regulators Open Forum that will answer your critical questions about regulatory expectations.
8.       NEW! 15 Bioprocessing Problem-Solving Moderated Discussions to help you move drug candidates closer to approval.
9.       The Right Partners for You. Form collaborations and alliances with innovators, suppliers, academia and associations to reach new heights of clinical and commercial success
10.   The Most Comprehensive Science. Capitalize on the latest data-driven research and moderated discussions to move towards commercialization and streamlined development and production from upstream to drug product/fill-finish.

Download the brochure for more information about BPI 2015: http://bit.ly/1NBdz3I

As a valued member of our LinkedIn community, you get $100 off the current rate when you register using code XB15171LINK: http://bit.ly/1NBdz3I

We hope to see you in Boston next month!

Best,
The BPI 2015 Team
@IBCUSA
#BPIConf




Share this article with your social network, just click below to share now!


Monday, September 14, 2015

The 4Vs framework and its application in Biopharmaceutical manufacturing

Bioprocessing is an endeavor with some specific challenges associated with it, such as how we might implement single-use technologies or gain regulatory approval for new drugs. It seems to me, however, that it is easy to become so focused on topics such as these that we overlook applying established methods and practices used in a broad array of industries to improve our own. One such framework that could be applied to our sector is an analysis of the 4Vs of volume, variety, variation and visibility. Considering these parameters can help us make decisions about how to best organize biopharmaceutical manufacturing operations.

Volume: The number of doses of a biopharmaceutical to be manufactured varies considerably between drug products. Blockbuster products and products used to manage chronic diseases over long periods of time might be manufactured in large volumes. Due to the specific nature of biopharma drugs the patients that will respond to them can be small and the number of doses required not nearly so many. Orphan drugs for treating relatively rare diseases are a good example of products where the number of doses per year to be manufactured might be very low. Taking this to an extreme, personalized medicines and cell therapies are likely to be required is such small volumes that they are challenging existing industry processing technologies, supply networks and regulatory frameworks in order that they can be successfully commercialized.

Variety: Often linked by an inverse relationship to volume, variety refers to the number of different products an operation must deliver. In the above example of personalized medicine the variety of products to be produced may be very high as the products are in essence customized to the patient receiving them. Less variety tends to imply higher volume production and perhaps less operational complexity. Biopharmaceutical companies often strive to develop platform manufacturing processes capable of delivering a variety of products within their portfolio without adding to this complexity.

Variation: The degree to which demand for the product varies can have a significant impact on operation design. This variation can be more predictable, such as with the seasonal flu vaccines or less predictable, perhaps driven by competitor or regulatory activity. Responding to variations in demand can be a significant challenge for the biopharmaceutical industry where making process changes including process scale-up be a slow process with technical and regulatory challenges. Failure to design operations with sufficient agility to respond to demand fluctuations can result in increased lead times and patients not receiving medicines at the time they are required.

Visibility: Biomanufacturing operations are typically exposed to a high level of internal and external scrutiny due to the regulated nature of the industry. Process visibility is a term often used to describe operations that deliver services in which the customer is typically heavily involved in their design and operation. An example in biologics manufacturing are the use of Contract Manufacturing Organizations (CMOs). Once the decision has been made to outsource production, the management of the relationship between customer and contractor must be given significant attention to ensure successful delivery of drugs to patients and the sponsor must address issues such as relinquishing of some control.

Consideration of the 4Vs can help shape the design of biomanufacturing operations. For instance, high volume-low variety operations are typically more repetitive in nature and may suggest continuous biomanufacturing is an appropriate strategy. Companies requiring a small number of doses of a large number of products will need to design operations that permit a greater level of complexity and more intermittent processes. It is a framework worth reviewing when considering the future design of your companies bioprocessing footprint.




Join me at #BPIconf
Contact me at nick.hutchinson@parker.com

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.



Share this article with your social network, just click below to share now!


Wednesday, September 9, 2015

The 3 Biggest Challenges Facing Regenerative Medicine Developers

 
Dr. Julie Allickson, Director of the Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine and Wake Forest School of Medicine - also a keynote speaker at this years Cell Therapy Bioprocessing & Commercialization event - sat down with us for a podcast interview. During the interview, Dr. Allickson discusses the future challenges for regenerative medicine developers, how pharma companies that are developing regenerative medicine therapies can benefit from the academic model for translation, the regulatory hurdles that regenerative medicine developers face, the key differences between the industry in North America, Europe and Asia, as well as her talk at this years meeting. Below you will find a teaser from the interview...Interested in hearing more? Access the complete interview now...


Where do you see the biggest challenges facing regenerative medicine developers over the next five years?

I think there are several different challenges, but when I really try to add those up I feel that there is a lot that we need to develop yet to get a robust manufacturing process. I think there is a lot that goes into making sure that the product is safe and meeting all the requirements for the regulators. But also, as we are looking at scaling up, scaling out the products, I think that there are a lot of efforts that we still need to put into that.

The other piece would be looking at automation and really pushing the automation to decrease what I’m going to say is the “human factor”, which can bring error and, actually, it would be much more timely. So, I think that the field really needs to push for the automation to be able to get more of a robust manufacturing process.

We actually just published a paper in February in stem cells translational medicine with Josh Hunsberger as the primary author, but really looking at the roadmap for tissue engineering and regenerative medicine in the manufacturing space. I believe that that’s definitely one of the challenges, but I think, also, we have challenges in clinical trial design.

There is a lot of failure – I would say – in clinical trials as we are learning, but I think it is getting better. As we nail down the appropriate patient populations, we’re not so broad and incorporate control groups and also really being thoughtful as we are looking at the end points in clinical trials. It is very critical as we’re selecting what matches up with the potency of the product. I think that’s definitely key.

Then, I would say third would be regulatory considerations. As we move forward, we know it’s really a new paradigm – regenerative medicine – in healthcare and I think that gives us the opportunity to be able to voice our concerns, educate the regulators so that they really understand what we need.

So, I think it is definitely communication, educating the regulators and I think that the more opportunity that we have to facilitate those discussions, the better place that we’ll be in because there is such an opportunity for healthcare if we can accelerate the commercialization of some of these products.


Want to hear more from Dr. Allickson? Join her in Alexandria, VA for Cell Therapy Bioprocessing & Commercialization, September 30 - October 2, 2015 - where Dr. Allickson will have a keynote address titled "Academic Model for Translation of Regenerative Medicine Including Tissue-Engineered Products in the 21st Century: What are the Pathways? What are the Barriers?"


We hope to see you in a few weeks!


Share this article with your social network, just click below to share now!


Thursday, September 3, 2015

Labor Day Weekend Sale! Save 30% off IBC’s Antibody Engineering & Therapeutics event


Take advantage of this special Labor Day Weekend offer and save 30% to Antibody Engineering & Therapeutics! Register with code AE201530 to activate your 30% discount off the standard rates to IBC’s 26th Annual Antibody Engineering & Therapeutics event taking place December 7-10, 2015 in San Diego, CA. Visit the website for full event details.

This limited-time offer expires on Monday, September 7th | Register here.

Now in its 26th year, IBC's Antibody Engineering & Therapeutics is the largest and most trusted antibody engineering and therapeutics event in the industry. As the leader in this space, we’ve continued to provide an impressive collection of world-renowned and highly-published academic and industry scientists, who share the latest science, strategies and preclinical/clinical development efforts. Connect with 700+ experts to discover, engineer and develop novel and next-generation antibody modalitites across diverse disease indications.

Activate your 30% savings now with code AE201530! Offer expires 9/7

Qualifications, rules and regulations: 
Offer cannot be applied retroactively to confirmed or pending registrations from today's date and prior. 30% discount cannot be combined with any team discounts or other promotions and/or discount offers. Discount is only valid from September 3rd – September 7th, 2015. All registrations are subject to IIR/IBC approval. Discount cannot be applied to the Academic/Government Rates.


Share this article with your social network, just click below to share now!


Friday, August 28, 2015

LAST CHANCE | Save $550 to Antibody Engineering & Therapeutics

As the largest and most trusted antibody engineering and therapeutics event in the industry, IBC's Antibody Engineering & Therapeutics continues to showcase an impressive collection of world-renowned and highly-published academic and industry scientists, as they share the latest science, strategies and preclinical/clinical development efforts.

Get a sneak peek at the high caliber sessions and happenings of the event by watching the 2014 event highlights:



By attending this event, you will learn from 120+ speakers and connect with over 700 of your peers to help you discover, engineer and develop novel and next-generation antibody modalities. In addition, you will gain fresh ideas and new perspectives to accelerate your current project by viewing over 100 academic and industry poster presentations covering the latest cutting edge antibody research.

To see full session & speaker details, download the brochure.

But you have to be registered first to get access! Register today to take advantage of the early-bird savings of up to $550. Be sure to use code D15172BLOG. The savings expire tomorrow, Friday, August 28th—so hurry! Register now.



Share this article with your social network, just click below to share now!


Monday, August 17, 2015

Overcoming the challenges of high concentration protein formulations


There is a trend within the biopharmaceutical industry for companies to develop formulations for protein drugs with extremely high concentrations. Such formulations provide advantages to both patients and clinicians as they allow biological drugs to be delivered via the sub-cutaneous route of administration rather than by the more traditional intravenous route. Sub-cutaneous delivery allows patients to receive treatment in a clinic or even administer the drug themselves while intravenous infusions tend to require the patient to make a hospital visit which increases the cost of treatment. However, if a patient is able to self-administer the pharmaceutical drug they require to treat a chronic disease then they are more able to lead a normal life which is a tremendous benefit (Highly concentrated protein formulations: Finding solutions for the next generation of parenteral biologics, J Kling, 2014).
The challenge of processing highly concentrated protein drugs
Being able to provide a biopharmaceutical at a formulated concentration of 100 g/L or higher can be a means by which biopharmaceutical companies can gain an advantage over one another in an increasingly competitive marketplace. However, developing such formulations is no trivial task because at high concentrations, protein solutions can become very viscous and difficult to process and the proteins themselves can aggregate. The viscosity of these solutions can challenge filtration equipment and can lead to significant yield losses in the final stages of the processes when the product has its greatest value. Protein aggregation can lead to a reduction in the pharmaceutical’s potency and can even trigger an immune reaction to the drug.

Innovation at the interface with formulations

The topic of high concentration protein formulations will be covered at the BioProcess International Conference & Exposition 2015 to be held on October 26-29 in Boston, MA. Sigma S Mostafa, PhD, Director, Process Development at KBI Biopharma Inc will be chairing a session on ‘Innovation at the Interface with Formulations’. Pfizer are scheduled to present on ‘Challenges of High Concentration Formulations – Dealing with Viscosity and Excipients’ while Mark Moody will present on ‘Opportunities and Challenges of High Concentration Biologics: Case Studies’. The session promises to address some of the key issues manufacturers face when processing concentrated protein solutions.

Have your say

Protein biopharmaceuticals are being formulated to 100 g/L even 200 g/L, however, some have proposed that concentrating to 500 g/L may be desirable. In your opinion, what is the maximum concentration that is required or attainable for protein drug formulations?

Join me at #BPIconf
Contact me at nick.hutchinson@parker.com
Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.





Share this article with your social network, just click below to share now!


Monday, August 10, 2015

Designing and building next gen biomanufacturing facilities in Asia


Singapore has become a significant hub for biopharmaceutical companies looking to manufacture in Asia. Locating manufacturing facilities in Asia allows companies to product biologics close to important and expanding markets and improve their cost structure. Amgen is one such company that is increasing its presence in Asia with a $160 million investment to build a manufacturing facility in Singapore for the production of denosumab the active ingredient in Prolia and XGEVA. Regulatory filing is expected to take place in 2016.

Amgen’s next generation biomanufacturing facility
Kimball Hall, Vice President of Manufacturing and site head at Amgen Singapore Manufacturing Pte. Ltd. will be presenting at Bioprocess International’s 2015 Conference and Exhibition in Octoberon “Amgen’s next generation biomanufacturing facility”.

The facilities smaller, modular design will allow it to be readily replicated for future facilities in order to increase capacity while expanding the company’s global network and reach. It will heavily utilize single-use technologies including bioreactors up to 2000L in scale. Also of interest is Amgen’s choice to make use of continuous processing steps which is a topic I’ve covered in this blog previously.

Next gen facility saves time and money
The approach that Amgen has adopted is set to save the company money. In a recent interview Kimball was quoted as saying Amgen’s “next-generation biomanufacturing require ¼ of the capital costs, 1/3 of the operating expense; and half of the construction time” (Inside Look at Amgen’s Next-Gen Biomanufacturing by Denice Cabel).

The environmental impact of single-use technologies
Interestingly, Amgen considers the use of disposable technology as being more environmentally friendly than traditional stainless steel plants. This for many is counterintuitive as they see the single-use technologies made from plastics as part of a throwaway culture but they neglect to consider the considerable energy and water requirements needed to produce the clean steam, WFI and cleaning solutions that are required to prevent contaminations in reusable bioprocessing equipment.

Global supply chain networks are becoming increasingly important as was highlighted in last week’s post on final fill finish operations. Interestingly the trend to develop these networks is driving innovation and the adoption of novel technologies.
Have your say
Singapore has a significant cluster of biomanufacturing facilities and is important on the global stage. Where do you see the next big hub developing?

Join me at #BPIconf

Contact me at nick.hutchinson@parker.com

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!